vs
CVB FINANCIAL CORP（CVBF）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是CVB FINANCIAL CORP的1.5倍（$207.3M vs $133.8M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 8.4%），CVB FINANCIAL CORP自由现金流更多（$217.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 2.8%）
CVB金融集团是一家美国银行控股公司，运营公民商业银行，主要服务加利福尼亚州市场，面向中小企业、专业机构及个人客户提供商业银行、个人银行、财富管理等多元金融服务，核心业务包含商业贷款、存款账户、资产管理等。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CVBF vs RARE — 直观对比
营收规模更大
RARE
是对方的1.5倍
$133.8M
营收增速更快
RARE
高出17.5%
8.4%
自由现金流更多
CVBF
多$318.1M
$-100.8M
两年增速更快
RARE
近两年复合增速
2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $133.8M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 55.6% | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | 8.4% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.41 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVBFRARE
| Q4 25 | $133.8M | $207.3M | ||
| Q3 25 | $128.6M | $159.9M | ||
| Q2 25 | $126.4M | $166.5M | ||
| Q1 25 | $126.7M | $139.3M | ||
| Q4 24 | $123.5M | $164.6M | ||
| Q3 24 | $126.5M | $139.5M | ||
| Q2 24 | $125.3M | $147.0M | ||
| Q1 24 | $126.6M | $108.8M |
净利润CVBFRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $52.6M | $-180.4M | ||
| Q2 25 | $50.6M | $-115.0M | ||
| Q1 25 | $51.1M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $51.2M | $-133.5M | ||
| Q2 24 | $50.0M | $-131.6M | ||
| Q1 24 | $48.6M | $-170.7M |
营业利润率CVBFRARE
| Q4 25 | 55.6% | -54.7% | ||
| Q3 25 | 53.7% | -106.9% | ||
| Q2 25 | 54.4% | -64.8% | ||
| Q1 25 | 54.9% | -102.6% | ||
| Q4 24 | 55.1% | -74.3% | ||
| Q3 24 | 53.5% | -94.6% | ||
| Q2 24 | 54.9% | -79.1% | ||
| Q1 24 | 52.8% | -151.9% |
净利率CVBFRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | 40.9% | -112.8% | ||
| Q2 25 | 40.0% | -69.0% | ||
| Q1 25 | 40.3% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 40.5% | -95.7% | ||
| Q2 24 | 39.9% | -89.5% | ||
| Q1 24 | 38.4% | -156.8% |
每股收益（稀释后）CVBFRARE
| Q4 25 | $0.41 | $-1.28 | ||
| Q3 25 | $0.38 | $-1.81 | ||
| Q2 25 | $0.37 | $-1.17 | ||
| Q1 25 | $0.36 | $-1.57 | ||
| Q4 24 | $0.36 | $-1.34 | ||
| Q3 24 | $0.37 | $-1.40 | ||
| Q2 24 | $0.36 | $-1.52 | ||
| Q1 24 | $0.35 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $376.4M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.3B | $-80.0M |
| 总资产 | $15.6B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CVBFRARE
| Q4 25 | $376.4M | $421.0M | ||
| Q3 25 | $783.9M | $202.5M | ||
| Q2 25 | $738.6M | $176.3M | ||
| Q1 25 | $529.1M | $127.1M | ||
| Q4 24 | $204.7M | $174.0M | ||
| Q3 24 | $453.5M | $150.6M | ||
| Q2 24 | $844.2M | $480.7M | ||
| Q1 24 | $949.6M | $112.3M |
股东权益CVBFRARE
| Q4 25 | $2.3B | $-80.0M | ||
| Q3 25 | $2.3B | $9.2M | ||
| Q2 25 | $2.2B | $151.3M | ||
| Q1 25 | $2.2B | $144.2M | ||
| Q4 24 | $2.2B | $255.0M | ||
| Q3 24 | $2.2B | $346.8M | ||
| Q2 24 | $2.1B | $432.4M | ||
| Q1 24 | $2.1B | $140.3M |
总资产CVBFRARE
| Q4 25 | $15.6B | $1.5B | ||
| Q3 25 | $15.7B | $1.2B | ||
| Q2 25 | $15.4B | $1.3B | ||
| Q1 25 | $15.3B | $1.3B | ||
| Q4 24 | $15.2B | $1.5B | ||
| Q3 24 | $15.4B | $1.5B | ||
| Q2 24 | $16.2B | $1.6B | ||
| Q1 24 | $16.5B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $221.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $217.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | 162.4% | -48.6% |
| 资本支出强度资本支出/营收 | 3.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $391.5M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CVBFRARE
| Q4 25 | $221.4M | $-99.8M | ||
| Q3 25 | $81.5M | $-91.4M | ||
| Q2 25 | $53.1M | $-108.3M | ||
| Q1 25 | $41.9M | $-166.5M | ||
| Q4 24 | $249.8M | $-79.3M | ||
| Q3 24 | $71.4M | $-67.0M | ||
| Q2 24 | $26.1M | $-77.0M | ||
| Q1 24 | $77.5M | $-190.7M |
自由现金流CVBFRARE
| Q4 25 | $217.3M | $-100.8M | ||
| Q3 25 | $80.7M | $-92.7M | ||
| Q2 25 | $52.3M | $-110.7M | ||
| Q1 25 | $41.2M | $-167.8M | ||
| Q4 24 | $244.6M | $-79.5M | ||
| Q3 24 | $70.2M | $-68.6M | ||
| Q2 24 | $24.4M | $-79.0M | ||
| Q1 24 | $77.3M | $-193.9M |
自由现金流率CVBFRARE
| Q4 25 | 162.4% | -48.6% | ||
| Q3 25 | 62.8% | -58.0% | ||
| Q2 25 | 41.4% | -66.5% | ||
| Q1 25 | 32.5% | -120.5% | ||
| Q4 24 | 198.0% | -48.3% | ||
| Q3 24 | 55.5% | -49.2% | ||
| Q2 24 | 19.5% | -53.7% | ||
| Q1 24 | 61.1% | -178.2% |
资本支出强度CVBFRARE
| Q4 25 | 3.0% | 0.5% | ||
| Q3 25 | 0.7% | 0.8% | ||
| Q2 25 | 0.7% | 1.5% | ||
| Q1 25 | 0.5% | 1.0% | ||
| Q4 24 | 4.2% | 0.1% | ||
| Q3 24 | 1.0% | 1.2% | ||
| Q2 24 | 1.4% | 1.4% | ||
| Q1 24 | 0.1% | 3.0% |
现金转化率CVBFRARE
| Q4 25 | — | — | ||
| Q3 25 | 1.55× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 0.82× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.39× | — | ||
| Q2 24 | 0.52× | — | ||
| Q1 24 | 1.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVBF
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
